Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abbott Medical Devices
This is a post-market clinical study of HM II patient management practices to be conducted in the United States.
Subjects will be randomized in a 1:1 fashion to the following research drug groups:
1. Treatment Arm: Warfarin (INR target: 2.0-2.5, median: 2.25) + Placebo (1 pill/day)
2. Control Arm: Warfarin (INR target: 2.0-2.5, median: 2.25) + ASA Therapy (81mg/day)
The study will investigate if subjects in the Treatment Arm experience a reduced incidence of non-surgical bleeding, without an increased risk of thromboembolic events.
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject is receiving the HM II per standard of care (SOC) in accordance with the FDA approved indications for use
Subject is ≥ 50 years of age
Subject is receiving the HM II as their first LVAD
Subject or legally authorized representative (LAR) has signed an informed consent form (ICF).
You may not be if
Existence of ongoing mechanical circulatory support (MCS) other than intra-aortic balloon pump or Impella® devices
Participation in any other clinical investigation(s) involving an MCS device, or an investigation(s) that is likely to confound study results or affect study outcome
Antiplatelet therapy is mandated for other conditions, in particular: a) recent coronary artery stenting (≤ 6 months), b) carotid artery disease, and c) other conditions where the investigator is not comfortable leaving subjects off-ASA or starting ASA post LVAD implantation. In situations where the investigator is uncertain, the Steering Committee can provide recommendation to the investigator as needed.
Subjects in whom heart transplantation is expected in ≤ 6 months